ClearPoint Neuro (NASDAQ:CLPT) Stock Rating Upgraded by Wall Street Zen

ClearPoint Neuro (NASDAQ:CLPT) was upgraded by analysts at Wall Street Zen from a “strong sell” rating to a “hold” rating in a report released on Saturday, Wall Street Zen reports.

A number of other equities research analysts have also recently issued reports on CLPT. Lake Street Capital set a $25.00 price target on shares of ClearPoint Neuro in a report on Tuesday, August 4th. Weiss Ratings restated a “sell (d-)” rating on shares of ClearPoint Neuro in a research note on Thursday, October 15th. Finally, Stifel Nicolaus lowered their price target on ClearPoint Neuro from $22.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $24.33.

ClearPoint Neuro Price Performance

CLPT stock opened at $10.67 on Friday. ClearPoint Neuro has a 12 month low of $8.27 and a 12 month high of $24.75. The company has a market capitalization of $341.97 million, a P/E ratio of -8.82 and a beta of 1.38. The company has a debt-to-equity ratio of 1.86, a current ratio of 6.76 and a quick ratio of 5.77. The firm’s fifty day simple moving average is $12.51 and its 200-day simple moving average is $13.00.

ClearPoint Neuro (NASDAQ:CLPT) last issued its quarterly earnings data on Wednesday, October 28th. The company reported ($0.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.08. The business had revenue of $12.07 million during the quarter, compared to analysts’ expectations of $12.30 million. ClearPoint Neuro had a negative return on equity of 170.24% and a negative net margin of 79.43%. As a group, equities research analysts forecast that ClearPoint Neuro will post -1.17 earnings per share for the current year.

Institutional Investors Weigh In On ClearPoint Neuro

Several institutional investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc purchased a new stake in ClearPoint Neuro during the 2nd quarter valued at $49,000. Versant Capital Management Inc lifted its stake in ClearPoint Neuro by 5,568.9% during the second quarter. Versant Capital Management Inc now owns 3,458 shares of the company’s stock worth $62,000 after purchasing an additional 3,397 shares in the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of ClearPoint Neuro during the second quarter worth about $75,000. Man Group plc acquired a new stake in shares of ClearPoint Neuro in the second quarter valued at about $213,000. Finally, Lodestone Wealth Management LLC increased its stake in shares of ClearPoint Neuro by 10.1% during the 3rd quarter. Lodestone Wealth Management LLC now owns 12,221 shares of the company’s stock valued at $149,000 after acquiring an additional 1,123 shares during the last quarter. 30.08% of the stock is owned by institutional investors.

ClearPoint Neuro Company Profile

ClearPoint Neuro, Inc is a medical technology company that develops and commercializes platforms for minimally invasive procedures involving the brain. Its technology is designed to help physicians plan, navigate and deliver treatments with real-time magnetic resonance imaging (MRI) guidance, supporting more precise access to targeted areas of the brain.

The company’s principal product is the ClearPoint Neuro Navigation System, which uses specialized software, instruments and accessories to guide neurosurgical procedures inside an MRI scanner.